Comparative Pharmacology
Head-to-head clinical analysis: MODEYSO versus MODICON 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MODEYSO versus MODICON 21.
MODEYSO vs MODICON 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
400 mg orally once daily with food
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
None Documented
None Documented
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total)
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive